Glenmark Pharma gets USFDA nod for seizure treatment drug
India | February 03, 2021 10:30 ISTShares of Glenmark Pharmaceuticals were trading 2.41 per cent higher at Rs 499.10 apiece on the BSE.
Shares of Glenmark Pharmaceuticals were trading 2.41 per cent higher at Rs 499.10 apiece on the BSE.
Drug major Glenmark Pharma on Monday said it has received tentative approval from the US health regulator for anticoagulant Dabigatran Etexilate capsules.
Drug major Glenmark Pharma on Wednesday said it has received final approval from the US health regulator for Tacrolimus capsules, used as immuno-suppressant.
Glenmark Pharmaceuticals on Monday said it has received approval from the US health regulator to market Sirolimus tablets, an immunosuppressant, in the American market.
Glenmark Pharma on Wednesday announced the launch of its generic version of Nintedanib (NINDANIB), used for the treatment of pulmonary fibrosis, in India.
Glenmark Pharmaceuticals on Thursday announced top-line results from a Phase 3 clinical trial in mild to moderate COVID-19 patients, conducted across seven clinical sites in India.
According to Glenmark, 40 per cent faster achievement of "clinical cure" was witnessed in the third phase of the clinical trials of Favipiravir involving 150 patients with mild to moderate COVID-19 across seven clinical sites in India.
Glenmark Pharmaceuticals on Tuesday said its generic version of antiviral drug Favipiravir, FabiFlu, is more economical and effective than other drugs available in the market approved for emergency use for treatment of COVID-19.
Shares of Glenmark Pharmaceuticals on Monday tumbled nearly 6 per cent after India's drug regulator sought clarification from the company over its alleged "false claims" about the use of anti-viral FabiFlu on COVID-19 patients with comorbidities and also over the "pricing" of the drug.
The Drug Controller General of India (DCGI) issued notices to Glenmark seeking clarification from the company regarding the false claim that its antiviral drug Fabiflu, is effective on COVID-19 patients with co-morbidities.
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet. In a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab, it said.
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
Shares of Glenmark Pharmaceuticals on Monday rallied 27 per cent after the company said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Glenmark Coronavirus medicine FabiFlu launched at Rs 103 per tablet: Glenmark's FabiFlu has been approved for coronavirus treatment in India. FabiFlu is the first oral Favipiravir-approved medication in India for the treatment of COVID-19, the company said in a statement.
Glenmark has become the first pharmaceutical company in India to receive regulatory approval for oral antiviral favipiravir, for the treatment of mild to moderate COVID-19.
Shares of Glenmark Pharmaceuticals on Monday rallied 20 per cent after the company said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Drug major Glenmark Pharmaceuticals has become the first Indian company to commercially launch an antiviral drug for the treatment of mild to moderate COVID-19 patients, after it received the Indian drug regulator Drug Controller General of India (DCGI) approval.
Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
Drug major Glenmark Pharmaceuticals on Friday said it has received final nod from the health regulator for Fingolimod capsules.
Glenmark has successfully developed the active pharma ingredient (API) and the formulations for the product through its in-house R&D team. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections.
Top News
Latest News
